Tag: Entry inhibitor

Enfuvirtide, commonly known by its research code T20 and brand name Fuzeon, was the first-in-class HIV fusion inhibitor approved by the FDA in 2003, marking a significant milestone in antiretroviral therapy. This potent peptide drug revolutionized treatment for individuals with drug-resistant HIV by uniquely blocking the virus from entering healthy immune cells. However, the term 'T20' also appears as a pill imprint for many other medications, which can cause confusion.

Enfuvirtide was the first drug approved in the fusion inhibitor class of antiretrovirals, marking a new approach in HIV treatment. This synthetic peptide is used as part of a combination therapy for patients with multidrug-resistant HIV-1 infection, and its classification highlights its unique mechanism of blocking viral entry.

Fuzeon, with the generic name enfuvirtide, was the first HIV fusion inhibitor approved by the U.S. Food and Drug Administration in 2003, representing a new front in the battle against HIV/AIDS. This injectable drug, a fusion inhibitor, targets an early stage of the viral lifecycle and is reserved for specific, treatment-experienced patients with multidrug-resistant HIV.

Hepatitis D is the most severe form of viral hepatitis, and for decades, treatment options were severely limited. However, the approval of Hepcludex has introduced a new class of medication, known as an entry inhibitor, that effectively blocks both the hepatitis B and delta viruses from infecting healthy liver cells.